References
- 1. Tian Z, van Velkinburgh JC, Wu Y, Ni B. Innate lymphoid cells involve in tumourigenesis. Int J Cancer. 2015; doi: 10.1002/ijc.29443.
- 2. Fuchs A, Colonna M. Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumours of the gastrointestinal tract. Curr Opin Gastroenterol 2013; 29: 581-7.
- 3. Constantinides MG, McDonald BD, Verhoef PA, Bendelac A. A committed precursor to innate lymphoid cells. Nature 2014; 508: 397-401.
- 4. Spits H, Artis D, Colonna M et al. Innate lymphoid cells- a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-9.
- 5. Montaldo E, Vacca P, Moretta L, Mingari MC. Development of human natural killer cells and other innate lymphoid cells. Semin Immunol 2014; 26: 107-13.
- 6. Yagi R, Zhong C, Northrup DL et al. The transcription factor GATA3 is critical for the development of all IL-7Ralpha-expressing innate lymphoid cells. Immunity 2014; 40: 378-88.
- 7. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodelling. Nat Immunol 2011; 12: 21-7.
- 8. Jovanovic I, Pejnovic N, Radosavljevic G et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoural accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2013; 134: 1669-82.
- 9. Liu J, Duan Y, Cheng X et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011; 407: 348-54.
- 10. Kirchberger S, Royston DJ, Boulard O et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013; 210: 917-31.
- 11. Ikutani M, Yanagibashi T, Ogasawara M et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumour immunity. J Immunol 2012; 188: 703-13.
- 12. Moro K, Yamada T, Tanabe M et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010; 463 (7280): 540-4.
- 13. Saenz SA, Siracusa MC, Perrigoue JG et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature. 2010; 464: 1362-6.
- 14. Neill DR, Wong SH, Bellosi A et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010; 464(7293): 1367-70.
- 15. Hurst SD, Muchamuel T, Gorman DM et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol. 2002; 169: 443-53.
- 16. Chang YJ, Kim HY, Albacker LA et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011; 12: 631-8.
- 17. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012; 36: 451-63.
- 18. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage-CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012; 188: 1503-13.
- 19. Barlow JL, Bellosi A, Hardman CS et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012; 129: 191-8.
- 20. Kim HY, Chang YJ, Subramanian S et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012; 129: 216-27.
- 21. Yasuda K, Muto T, Kawagoe T et al. Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci U S A. 2012; 109: 3451-6.
- 22. Wilhelm C, Hirota K, Stieglitz B et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011; 12: 1071-7.
- 23. Monticelli LA, Sonnenberg GF, Abt MC et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011; 12: 1045-54.
- 24. Mirchandani AS, Salmond RJ, Liew FY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012; 33: 389-96.
- 25. Kiessling, R. Klein, E., Pross, H. & Wigzell, H. “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukaemia cells. Characteristics of the killer cell. Eur. J. Immunol. 1975; 5: 117-121.
- 26. Vonarbourg C, Mortha A, Bui VL et al. Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt+ innate lymphocytes. Immunity 2010; 33: 736-751
- 27. Bernink JH, Peters CP, Munneke M et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013; 14: 221-9.
- 28. Klose CS, Flach M, Möhle L et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 2014; 157: 340–56.
- 29. Maloy KJ, Uhlig HH. ILC1 populations join the border patrol. Immunity 2013; 38: 630-2.
- 30. Cella M, Fuchs A, Vermi W et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009; 457: 722-725.
- 31. Takayama T, Kamada N, Chinen H et al. Imbalance of NKp44(þ)NKp46(−) and NKp44(−) NKp46(þ) natural killer cells in the intestinal mucosa of patients with Crohn’s disease. Gastroenterology 2010; 139: 882-892
- 32. Cella M, Otero K, Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci USA 2010; 107: 10961-10966.
- 33. Geremia A, Arancibia-Cárcamo CV, Fleming MP et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011; 208:1127-1133.
- 34. Cupedo T, Crellin NK, Papazian N et al. Human foetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009; 10: 66-74.
- 35. Ivanov II, Diehl GE, Littman DR. Lymphoid tissue inducer cells in intestinal immunity. Curr Top Microbiol Immunol 2006; 308: 59-82.
- 36. Takatori H, Kanno Y, Watford WT et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009; 206: 35-41.
- 37. Hepworth MR, Monticelli LA, Fung TC et al. Innate lymphoid cells regulate T-cell responses to intestinal commensal bacteria. Nature 2013; 498: 113-117.
- 38. Plunkett TA, Correa I, Miles DW and Taylor-Papadimitriou J. Breast cancer and the immune system: opportunities and pitfalls. J. Mammary Gland Biol. Neoplasia 2001. 6: 467–475.
- 39. Ito N, Nakamura H, Tanaka Y and Ohgi S. Lung carcinoma: analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer 1999. 85: 2359–2367.
- 40. Nishimura T, Nakui M, Sato M et al. The critical role of Th1-dominant immunity in tumour immunology. Cancer Chemother. Pharmacol. 2000. 46: 52–61.
- 41. Dobrzanski MJ, Reome JB, Hylindand JC and Rewers-Felkins KA. CD8 mediated type 1 antitumour responses selectively modulate endogenous differentiated and nondifferentiated t cell localization, activation, and function in progressive breast cancer. J. Immunol. 2006. 177: 8191–8201.
- 42. Vujanovic NL, Basse P, Herberman RB and Whiteside TL. Antitumour functions of natural killer cells and control of metastasis. Methods 1996. 9: 394–408.
- 43. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D and Levitsky H. The central role of CD41 T cells in the antitumour immune response. J. Exp. Med. 1998. 188: 2357–2368.
- 44. Ellyard JI, Simson L, Parish CR. Th2-mediated antitumour immunity: friend or foe? Tissue Antigens 2007. 70: 1–11.
- 45. Stout RD and Bottomly K. Antigen-specific activation of effector macrophages by IFN-g producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function of macrophages. J. Immunol. 1989. 142: 760–765.
- 46. Hu HM, Urba WJ and Fox BA. Gene-modified tumour vaccine with therapeutic potential shifts tumour-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 1998; 161: 3033-3041.
- 47. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2: 725-31.
- 48. Guedez L, Jensen-Taubman S, Bourboulia D et al. TIMP-2 targets tumour-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother 2012; 35: 502-12.
- 49. Koyasu S, Moro K. Type 2 innate immune responses and the natural helper cell. Immunology 2011; 132: 475-81.
- 50. Gabitass RF, Annels NE, Stocken DD et al. Elevated myeloid-derived suppressor cells in pancreatic, oesophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-30.
- 51. Li J, Razumilava N, Gores GJ et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest 2014; 124: 3241-51.
- 52. Patman G. Biliary tract. IL-33, innate lymphoid cells and IL-13 are required for cholangiocyte proliferation. Nat Rev Gastroenterol Hepatol 2014; 11: 456.
- 53. Pearson C, Uhlig HH, Powrie F. Lymphoid microenvironments and innate lymphoid cells in the gut. Trends Immunol 2012; 33: 289-96.
- 54. Chan IH, Jain R, Tessmer MS et al. Interleukin-23 is sufficient to induce rapid de novo gut tumourigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunol 2014; 7: 842-56.
- 55. Murugaiyan G, Saha B. Protumour vs antitumour functions of IL-17. J Immunol 2009; 183: 4169-75.
- 56. Kamanaka M, Huber S, Zenewicz LA, et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med 2011; 208: 1027-40.
- 57. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290: 827-38.
- 58. Vonarbourg C, Mortha A, Bui VL et al. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 2010; 33: 736-51.
- 59. Lim C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 2014; 25: 257-71.
- 60. Savan R, McFarland AP, Reynolds DA et al. A novel role for IL-22R1 as a driver of inflammation. Blood 2011; 117: 575-84.
- 61. Park O, Wang H, Weng H et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011; 54: 252-61.
- 62. Riccardi C, Santoni A, Barlozzari T, Puccetti P, Herberman RB. In vivo natural reactivity of mice against tumour cells. Int J Cancer 1980; 25: 475-486.
- 63. Wiltrout RH, Herberman RB, Zhang SR et al. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol 1985; 134: 4267-4275.
- 64. Gorelik E, Herberman RB. Radioisotope assay for evaluation of in vivo natural cell-mediated resistance of mice to local transplantation of tumour cells. Int J Cancer 1981; 27: 709-720.
- 65. Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB. Role of NK cells in the control of metastatic spread and growth of tumour cells in mice. Int J Cancer 1982; 30: 107-112.
- 66. Jovanovic I, Radosavljevic G, Milovanovic M et al. Suppressed Innate Immune Response against Mammary Carcinoma in BALB/C Mice. Ser J Exp Clin Res 2012; 13: 55-61.
- 67. Standish LJ, Sweet ES, Novack J et al. Breast cancer and the immune system. J Soc Integr Oncol 2008; 6: 158-168.
- 68. Strayer DR, Carter WA, Mayberry SD et al. Low natural cytotoxicity of peripheral blood mononuclear cells in individuals with high familial incidences of cancer. Cancer Res 1984; 44: 370-374.
- 69. Hacene K, Desplaces A, Brunet M, Lidereau R, Bourguignat A, Oglobine J. Competitive prognostic value of clinicopathologic and bioimmunologic factors in primary breast cancer. Cancer 1986; 57: 245-250.
- 70. Mohanty I, Nayak M, Nanda BK. Cell mediated immune status in carcinoma breast. Indian J Pathol Microbiol 1991; 34: 1-6.
- 71. Kauschke E, Komiyama K, Moro I, Eue I, König S, Cooper EL. Evidence for perforin-like activity associated with earthworm leukocytes. Zoology (Jena) 2001; 104: 13-24.